McKesson Extends CVS Distribution Deal Through 2032, Reaffirms Guidance
MCK sits 18% above its 52-week low of $723.68.
Summary
McKesson signed an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032, covering mail order, specialty, retail, and distribution centers. The deal locks in a major revenue stream for McKesson, which already counts CVS as a key customer. Management also reaffirmed fiscal 2027 adjusted EPS guidance of $44.20–$45.00 and long-term adjusted EPS growth of 13–16%, signaling confidence in the core business. The extension removes a key contract renewal risk and provides multi-year visibility. Next earnings call is November 4, 2026, where further updates are expected.
At the time of this announcement, MCK was trading at $851.75 on NYSE in the Trade & Services sector, with a market capitalization of approximately $99.5B. The 52-week trading range was $723.68 to $999.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.